Revive Therapeutics Ltd (OTCMKTS:RVVTF) expects to file an IND application with the US FDA for the potential treatment of coronavirus – Bucillamine. The company achieved significant progress under the leadership of Michael Frank, CEO, in just six months.
Bucillamine is a cysteine derived anti-inflammatory drug that has been in use for over 30 years to cure RA (Rheumatoid Arthritis) in South Korea and Japan. The company is repurposing drugs for the potential treatment of coronavirus and other new diseases.
The researchers at Revive are analyzing the data from potential use in curing acute gout flares. Its formulation completed phase II clinical study.
Bucillamine to cure inflammation in lungs
Bucillamine works by improving and restoring glutathione, an antioxidant. The research team at Revive brainstormed and decided to apply this drug to treat lung inflammation in patients, who are suffering from coronavirus, SARS, H1N1, and seasonal flu, because it successfully arthritis and gout using its anti-inflammatory properties.
Revive applied for UD FDA permission in April 2020 to conduct phase II clinical trial in coronavirus patients. Considering its positive interaction with the FDA, and the safety, efficiency, and composition of Bucillamine, the company received a go-ahead immediately and asked to submit an IND for Phase III trial. Frank said it is a great achievement for the company. The US FDA decision greatly improves the credibility of Revive. According to Frank, the company is incorporating the US FDA’s guidance into the IND package and will be ready by the end of this month.
Coronavirus treatment heads for phase III clinical study
Revive’s promising formulation for COVID-19 is heading for phase III clinical trial. The company also has an interesting and unique IP (intellectual property) for tapping into psychedelics, an emerging opportunity for mental wellness.
Treatment for autoimmune hepatitis
Revive is also progressing in the development of formulations using cannabidiol to cure auto-immune hepatitis.
Focus on psychedelics
Revive is focusing on psychedelics, a promising formulation for mental health. In 2019, the US FDA gave a nod for esketamine for the treatment of depression. It is the first formulation in the area of psychedelics to get the approval of the regulator in the US. A few months later, the regulators in the UK gave a nod for ketamine like formulation.